August 21, 2023 Eluminex Biosciences Completes Series B+ Financing, Raising More Than $50 M in 2023 典晶生物完成B+轮融资，2023年融资超过5000万美元
May 17, 2023 Eluminex Biosciences Receives Scientific Recognition for its Recombinant Human Collagen (rhCIII) Biosynthetic Cornea (EB-301) Program to Treat Corneal Blindness 典晶生物重组人胶原蛋白生物合成角膜项目在两个重要国际眼科学术会议上获奖
April 10, 2023 Eluminex Biosciences Announces Acceptance of Three Abstracts at Upcoming 2023 ARVO and ASCRS Annual Ophthalmology Meetings Regarding the EB-301 Biosynthetic Cornea Program
February 28, 2023 Eluminex Biosciences Closes $40+ Million Series B Financing 典晶生物完成超过4000万美元B轮融资，持续聚力眼科创新疗法及重组人胶原蛋白技术
February 20, 2023 Eluminex Announces Completion of Enrollment in Part A of the CLARITY Study 典晶生物完成生物合成角膜临床试验第一部分病人入组
January 19, 2022 Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings 典晶生物宣布从 Retinagenix Holdings 公司收购其 Zuretinol 资产
January 17, 2022 Eluminex Biosciences Successfully Completes Its First Pre-IND Meeting with the United States Food and Drug Administration for a Multivalent Fc Fusion Protein (EB-101) for the Treatment of Neovascular Age-related Macular Degeneration 典晶生物成功地与美国FDA就一种治疗新生血管年龄相关性黄斑病变的项目召开Pre-IND 会议
January 5, 2022 Eluminex Further Expands Leadership Team and Receives New Awards 典晶生物首席执行官张金忠博士荣膺两项人才称号并宣布进一步扩大公司高级管理层
December 30, 2021 Eluminex CEO Was Invited as a Guest Speaker at the DeviceChina 2021 and a Panelist at the China Healthcare Summit 典晶生物首席执行官张金忠博士受邀出席 DeviceChina 2021 和 China Healthcare Summit
October 13, 2021 Eluminex Biosciences Announces the Grand Opening of New Global Headquarters and Research and Development Center in Suzhou 典晶生物开业典礼成功举办
July 20, 2021 Eluminex Biosciences Expands Leadership Team and Receives Award 典晶生物宣布扩大高级管理层和荣获中国潜在独角兽企业称号
July 19, 2021 Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform 典晶生物获得珐博进生物合成角膜技术及重组III型人胶原蛋白平台独占许可权
November 27, 2020 Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing Portfolio | 专注眼科创新药研发的典晶生物完成五千万美元A轮融资 (qq.com)
